摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-Benzylamino-2-(1-hydroxymethyl-propylamino)-9-isopropyl-9H-purin-8-ol

中文名称
——
中文别名
——
英文名称
6-Benzylamino-2-(1-hydroxymethyl-propylamino)-9-isopropyl-9H-purin-8-ol
英文别名
6-(benzylamino)-2-(1-hydroxybutan-2-ylamino)-9-propan-2-yl-7H-purin-8-one
6-Benzylamino-2-(1-hydroxymethyl-propylamino)-9-isopropyl-9H-purin-8-ol化学式
CAS
——
化学式
C19H26N6O2
mdl
——
分子量
370.454
InChiKey
ATGNBOMVABHJMU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    27
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    102
  • 氢给体数:
    4
  • 氢受体数:
    6

反应信息

  • 作为产物:
    描述:
    8-bromoroscovitine hydrobromide 在 aq. base 作用下, 以89%的产率得到6-Benzylamino-2-(1-hydroxymethyl-propylamino)-9-isopropyl-9H-purin-8-ol
    参考文献:
    名称:
    2,6,8,9-Tetrasubstituted Purines as New CDK1 Inhibitors
    摘要:
    Purine inhibitors of cyclin-dependent kinases attract attention as potential anticancer drugs because their first representative roscovitine recently entered clinical trials. Although well described in terms of structure-activity relationships, we still present here a novel modification of the purine scaffold influencing their inhibitory properties. The introduced C-8 substituents, however, lowered the CDK inhibitory activity of roscovitine, whereas the antiproliferative potential of several derivatives remained high. (C) 2003 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(03)00632-2
点击查看最新优质反应信息

文献信息

  • 2,6,8,9-Tetrasubstituted Purines as New CDK1 Inhibitors
    作者:Jiřı́ Moravec、Vladimı́r Kryštof、Jan Hanuš、Libor Havlı́ček、Daniela Moravcová、Květoslava Fuksová、Marek Kuzma、René Lenobel、Michal Otyepka、Miroslav Strnad
    DOI:10.1016/s0960-894x(03)00632-2
    日期:2003.9
    Purine inhibitors of cyclin-dependent kinases attract attention as potential anticancer drugs because their first representative roscovitine recently entered clinical trials. Although well described in terms of structure-activity relationships, we still present here a novel modification of the purine scaffold influencing their inhibitory properties. The introduced C-8 substituents, however, lowered the CDK inhibitory activity of roscovitine, whereas the antiproliferative potential of several derivatives remained high. (C) 2003 Elsevier Ltd. All rights reserved.
查看更多